Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.11Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -2.44%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical successes and a strong financial position, but increased losses and expenses present challenges. Overall, the positive clinical outcomes suggest a promising outlook for the company despite the financial setbacks.Company Guidance
During the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call, the company provided detailed guidance on the progress and future plans for their lead drug, Haduvio. Trevi reported a net loss of $11.4 million for Q4 2024, compared to $7.8 million in the prior year, with R&D expenses rising to $9.3 million. The company successfully completed several clinical trials, including the Human Abuse Potential study, the CORAL study in IPF chronic cough, and the RIVER study in refractory chronic cough, with trials conducted across 11 countries. Trevi's cash reserves stood at $107.6 million, which includes a $50 million offering completed in December. The company’s cash runway extends into the second half of 2026, with expected quarterly cash burn of $12 million to $14 million in the first two quarters of 2025. Upcoming milestones include a Phase 2b readout for the CORAL trial expected in Q2 2025, and plans for an End-of-Phase 2 meeting with the FDA by the end of 2025. The company is also preparing for the next RCC trial while continuing to develop Haduvio for IPF and RCC.Positive Data Readouts
Trevi Therapeutics reported three positive data readouts in 2024, including the Human Abuse Potential study, the Sample Size Re-Estimation, and the RIVER study, indicating strong clinical progress for Haduvio.
Successful Human Abuse Potential Study
The Human Abuse Potential study showed statistically significant lower relative drug liking for nalbuphine compared to butorphanol, supporting its continued unscheduled status by the DEA.
RIVER Study Success
The RIVER study in RCC patients achieved a statistically significant reduction in 24-hour objective cough frequency, with a 57% placebo-adjusted change from baseline.
Financial Stability
Trevi completed a $50 million unwritten offering, resulting in cash, cash equivalents, and marketable securities totaling $107.6 million, providing a cash runway into the second half of 2026.
---
TRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $6.56 | $6.81 | +3.81% |
| Nov 06, 2024 | $3.10 | $2.90 | -6.45% |
| Aug 08, 2024 | $2.80 | $2.86 | +2.14% |
| May 07, 2024 | $2.90 | $2.64 | -8.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Trevi Therapeutics Inc (TRVI) report earnings?
Trevi Therapeutics Inc (TRVI) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Trevi Therapeutics Inc (TRVI) earnings time?
Trevi Therapeutics Inc (TRVI) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TRVI EPS forecast?
TRVI EPS forecast for the fiscal quarter 2025 (Q1) is -0.12.
---